18th Mar 2019 11:10
LONDON (Alliance News) - Evgen Pharma PLC on Monday said it expects the final read-out of its STEM trial in metastatic breast cancer to be announced early next week, in line with its guidance of first quarter of 2019.
Shares in the drug development company were trading up 8.4% at 16.52 pence each.
Evgen is currently carrying out two phase II trials for SFX-01, its lead development product, the STEM trial and the SAS trial.
The firm also added that it completed the treatment phase of the SAS trial with the last patient having received the final dose.
"Following advice from clinicians and statisticians, and in the light of commercial considerations, the company has decided to announce the primary endpoints, safety, tolerability and measures of blood flow in the brain, and secondary endpoints, relating to cognitive function, at the same time, rather than announcing them separately as previously indicated," Evgen explained.
It continued: "This approach fully protects the blinded integrity of the secondary endpoint data which continues to be collected post-dosing for six months from the initial haemorrhage."
The SAS trial will therefore remain fully blinded until all of the secondary endpoint data has been collected. The final read-out is expected in late summer 2019.
Related Shares:
EVG.L